Monthly Archive for: ‘January, 2010’
A thoroughly snowed-in
January is resolution time. A universal thought takes over: “I need to quit smoking, lose weight and call my mother more!” The IP Whiteboard team are not immune to this infectious optimism, and have put together some “IP resolutions” to kick off Twenty Ten. It’s not exactly Letterman’s Top 10, and we know resolutions aren’t always kept, but here goes!
The launch of the highly-anticipated Google “Nexus One” phone based on the “android” platform has the blogosphere buzzing about more than the technology. There is controversy over the name and who owns the intellectual property rights to “Nexus One”. The estate of science fiction writer Philip K Dick claims that the name has been taken from his novel Do Androids Dream of Electric Sheep? later made into the movie Blade Runner. The novel tells the story of a bounty hunter whose mission is to eliminate rogue “Nexus-6” series androids.
Belgian cartoon icon Tintin, created by Hergé in 1929, was arguably one of the most beloved fictional heroes of the 20th century. The comic strips follow the adventures of the young reporter as he investigates dangerous stories. Over 200 million copies of his adventures have been sold and he will soon also be the subject of a new film from Steven Spielberg, “The Adventures of Tintin: The Secret of the Unicorn” in 2011.
A recent decision by the United States Court of Appeals has again underscored the importance of ensuring that goods sold in the United States contain accurate patent markings. Mallesons partner John Swinson takes a close look at the salient features of the decision and the United States and Australian position on patent marking here.
It appears that Grey’s Anatomy star Eric Dane (aka “Dr McSteamy”) isn’t the only celebrity using copyright law to protect themselves from an invasion of their privacy: see our earlier post here.
The High Court has refused to grant special leave from a decision of the Full Federal Court (H Lundbeck A/S v Alphapharm Pty Ltd  FCAFC 70) concerning a patent for the (+)-enantiomer of citalopram, known as escitalopram.